Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

One-A-Day for cholesterol

This article was originally published in The Tan Sheet

Executive Summary

Bayer One-A-Day Cholesterol Plus is a "complete multivitamin that helps maintain healthy cholesterol levels and blood pressure levels already within the normal range," the firm maintains. The new SKU offers 10 mg policosanol to maintain cholesterol levels, as well as folic acid and calcium to help maintain healthy blood pressure. Cholesterol Plus is reaching retail outlets now and is available in 50-count ($8.49) and 100-count bottles ($14.99). National TV ads, promotional events and FSI drops are planned throughout 2005. The line extension is the first since One-A-Day Carb Smart launched in March 2004 (1"The Tan Sheet" March 22, 2004, p. 6)...

You may also be interested in...



Bayer Ready To Duke It Out With P&G On Rx-To-OTC Switches

Bayer looks to challenge Procter & Gamble's goal of becoming the leading Rx-to-OTC switch company

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel